Exelixis, Inc. NMS · EXEL

Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight

GlobeNewswire Inc. · 40d ago

Prediction: This Stock Could Double By 2031

The Motley Fool · 65d ago

Why Is Merck Stock Falling Tuesday?

Benzinga · 90d ago

The Best Healthcare Stocks to Buy With $50 Right Now

The Motley Fool · 124d ago

3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade

The Motley Fool · 142d ago

InSilico Lands Drug Discovery Deal After Hong Kong IPO

Benzinga · 186d ago

2 Healthcare Stocks to Buy for 2026 and Beyond

The Motley Fool · 193d ago

2 Under-the-Radar Stocks to Buy Heading Into 2026

The Motley Fool · 230d ago

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

GlobeNewswire Inc. · 262d ago

Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer

Benzinga · 265d ago

Pancreatic Endocrine Tumor Market Set to Witness Significant Growth During the Forecast Period (2025–2034) Owing to the Expected Launch of Therapies | DelveInsight

GlobeNewswire Inc. · 280d ago

Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years

The Motley Fool · 293d ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exelixis, Inc. - EXEL

GlobeNewswire Inc. · 345d ago

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors

GlobeNewswire Inc. · 361d ago

Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner

The Motley Fool · 365d ago

After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.

The Motley Fool · 366d ago

Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

Benzinga · 377d ago

CoreWeave, Super Micro Computer And Coinbase Are Among Top 11 Large-Cap Gainers Last Week (May 12-May 16): Are The Others In Your Portfolio?

Benzinga · 428d ago

Tech Stocks Edge Up, AMD Rallies 5%, 30-Year Yields Eye Danger Zone: What's Driving Markets Wednesday?

Benzinga · 432d ago

Why Exelixis Stock Is Skyrocketing Today

The Motley Fool · 432d ago

Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

GlobeNewswire Inc. · 433d ago

The Smartest Biotech Stocks to Buy With $50

The Motley Fool · 473d ago

Global Prostate Cancer Market to Reach USD 29.2 Billion by 2035, Driven by Aging Population and Awareness | Future Market Insights, Inc.

GlobeNewswire Inc. · 497d ago

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

Benzinga · 499d ago

Why Exelixis Stock Trounced the Market on Thursday

The Motley Fool · 513d ago